"An experimental study evaluating primary tumoroid sensitivity carried out by Ocello consisted of two parts. The first part evaluated intrinsic sensitivity of tumoroid lines to 2 therapeutic agents. The second part of this study tested T-cell mediated activity in the mixed tumoroid: matched PBMC co-culture. Overall, Ocello’s team has been knowledgeable, collaborative and responsive to Merck’s team requests. The results from the first part of the study confirmed Ocello’s expertise in providing screening capabilities with tumoroid lines. The final data was statistically significant and easy to interpret. The second part represented an exploratory study to both Merck and Ocello teams. While data reflects acceptable trends, the platform itself needs to be further optimized for screening. Advancing co-culture screening assays will enable Ocello to further progress testing of the immune-oncology-based therapeutics. In summary, Merck’s team has full confidence in future collaborations with Ocello, especially testing intrinsic tumoroid sensitivity to different therapeutics."
OcellO has not received any endorsements.